An observational study on dapagliflozin as an add-on therapy in type-2 diabetes mellitus patients in a tertiary care teaching hospital

Background: Diabetes mellitus is one of the prevalent morbid conditions all over world and no exception for India. Day by day, increase in its prevalence attributed to lifestyle derangements. To treat this condition many drugs treatment modalities are developed. Dapagliflozin an oral antidiabetic drug which acts sodium-glucose cotransport-2 (SGLT-2) inhibition. Its effectiveness seen type-2 diabetes makes it option Add-On therapy. Methods: This study a retrospective observational conducted at tertiary care hospital, GGH, Kurnool. The proposal has been reviewed approved institutional ethics committee. All adult diabetic patients who were prescribed during period January 2021 February 2022, total 45 included study. FBG, HbA1c collected through hospital records from General Medicine Endocrinology. Patients stopped before 3 months excluded. Results: Administration dapagliflozin as add-on therapy was found 26.63% decrease base line mean FBG 184 mg/dl 135 after 3mnoths significant (p=0.001). Mean significantly reduced 0.96 percentage point effectively when used combination with other OHAs or insulin within months. Conclusions: level fasting blood glucose Type-2DM patients, 3-month period. Due frequency Genitourinary tract infections, caution indicated while treating patients.